Skip to main content
Premium Trial:

Request an Annual Quote

Cleveland Hospital Selects GenomOncology's Software to Support NGS-based Cancer Test


NEW YORK (GenomeWeb) –GenomOncology said this week that University Hospitals' Case Medical Center and Seidman Cancer Center will use its GO Clinical Workbench software to launch their first next-generation sequencing-based cancer diagnostic test.

The UH centers will use GenomOncology's GO to manage the workflows they use to analyze raw sequence data all the way through to delivering actionable clinical reports, the company said. The system offers tools for things like checking the quality of sequencing runs and samples, and for annotating and reporting on tumor variants that will "allow us to quickly translate scientific findings into the higher quality patient care," Joseph Willis, division chief of clinical pathology at UH Case Medical Center, said in a statement. Customers can tailor the GO platform to their lab's specific needs and integrate it with existing infrastructure such as laboratory information management systems and so on.

Financial and other terms of the agreement were not disclosed.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.